By a News Reporter-Staff News Editor at Biotech Week -- A new study on Oncology is now available. According to news reporting originating from Urbana, Illinois, by NewsRx correspondents, research stated, "Oligonucleotides homologous to 3'-telomere overhang (T-oligos) trigger inherent telomere-based DNA damage responses mediated by p53 and/or ATM and induce senescence or apoptosis in various cancerous cells. However, T-oligo has limited stability in vivo due to serum and intracellular nucleases."
Our news editors obtained a quote from the research from the University of Illinois, "To develop T-oligo as an innovative, effective therapeutic drug and to understand its mechanism of action, we investigated the antitumor effects of T-oligo or T-oligo complexed with a novel cationic alpha helical peptide, PVBLG-8 (PVBLG), in a p53 null melanoma cell line both in vitro and in vivo. The uptake of T-oligo by MM-AN cells was confirmed by immunofluorescence, and fluorescence-activated cell sorting analysis indicated that the T-oligo-PVBLG nanocomplex increased uptake by 15-fold. In vitro results showed a 3-fold increase in MM-AN cell growth inhibition by the T-oligo-PVBLG nanocomplex compared with T-oligo alone. Treatment of preformed tumors in immunodeficient mice with the T-oligoPVBLG nanocomplex resulted in a 3-fold reduction in tumor volume compared with T-oligo alone. This reduction in tumor volume was associated with decreased vascular endothelial growth factor expression and induction of thrombospondin-1 expression and apoptosis. Moreover, T-oligo treatment downregulated procaspase-3 and procaspase-7 and increased catalytic activity of caspase-3 by 4-fold in MM-AN cells. Furthermore, T-oligo induced a 10-fold increase of senescence and upregulated the melanoma tumor-associated antigens MART-1, tyrosinase, and thrombospondin-1 in MM-AN cells, which are currently being targeted for melanoma immunotherapy. Interestingly, siRNA-mediated knockdown of p73 (4-10-fold) abolished this upregulation of tumor-associated antigens."
According to the news editors, the research concluded: "In summary, we suggest a key role of p73 in mediating the anticancer effects of T-oligo and introduce a novel nanoparticle, the T-oligo-PVBLG nanocomplex, as an effective anticancer therapeutic."
For more information on this research see: Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy. International Journal of Nanomedicine, 2014;9():43-53. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Oncology).
The news editors report that additional information may be obtained by contacting S.B. Uppada, University of Illinois, Dept. of Mat Sci & Engn, Urbana, IL, United States. Additional authors for this research include T. Erickson, L. Wojdyla, D.N. Moravec, Z.Y. Song, J.J. Cheng and N. Puri.
Keywords for this news article include: Antigens, Urbana, Illinois, Genetics, Oncology, p53 Gene, Treatment, Immunology, United States, Immunotherapy, Immunomodulation, Biological Factors, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC